5 of Last Week's Biggest Winners

Most of the major market indices took a hit last week, with the Nasdaq Composite leading -- err, bleeding -- the way with a 2.7% slide. But amid the mayhem, a handful of stock salmon swam upstream, deftly dodging the claws of savage bears. Here are five of the past week's biggest successes:

Company

March 18 Weekly Gain My Watchlist
Celera (Nasdaq: CRA  ) $8.40 33% Add
Lubrizol (NYSE: LZ  ) $133.75 27% Add
K-Sea (NYSE: KSP  ) $8.09 25% Add
Unilife (Nasdaq: UNIS  ) $5.31 25% Add
Golar LNG (Nasdaq: GLNG  ) $22.96 23% Add

Source: Barron's.

Celera came through with healthy gains, after Quest Diagnostics (NYSE: DGX  ) agreed to acquire its rival medical lab in a $671 million deal.

Not so fast! Quest's buyout offer would take Celera out at $8 a share. The market's assuming that either a bidding war will break out or that Quest will sweeten its offer. Several law firms are also trying to stir up class action lawsuits, suggesting that Celera is selling itself too cheap. In short, there may still be some fireworks here.

Lubrizol was the New York Stock Exchange's top performer on even bigger buyout news. Warren Buffett's Berkshire Hathaway (NYSE: BRK-B  ) is snapping up the lubricants giant in a $9.7 billion deal. I'm probably in no position to question Buffett, but where was this acquisitive spirit two years ago, when equity prices were much lower?

Another acquisition that fueled a big run-up was Kirby's deal to snap up oil tanker K-Sea Transportation. The news also sparked investor interest in K-Sea's peers, explaining the 23% pop in shares of Golar LNG.

Finally, Unilife headed higher after announcing that it was on track to begin producing its prefilled syringes, having cleared an essential regulatory milestone. Unilife further revealed that its CEO would make a sizable purchase of stock in the open market, which certainly didn't hurt its shares.

After a great week for these five stocks, let's see whether they'll be up for an encore.

Which of these five stocks do you think will continue to move higher? Share your thoughts in the comment box below.

Berkshire Hathaway and Quest Diagnostics are Motley Fool Inside Value choices. Berkshire Hathaway is a Motley Fool Stock Advisor recommendation. The Fool owns shares of Berkshire Hathaway. Motley Fool Alpha owns shares of Quest Diagnostics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Longtime Fool contributor Rick Munarriz enjoys cheering on winners and encouraging the losers. He does not own shares in any of the companies in this story. He is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 1461433, ~/Articles/ArticleHandler.aspx, 4/16/2014 7:10:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement